Top

Published in:

Open Access 01-02-2020 | Lymphoma | Original Article

X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic

Authors: Tao Xu, Qin Zhao, Wenyan Li, Xuemei Chen, Xiuhong Xue, Zhi Chen, Xiao Du, Xiaoming Bai, Qian Zhao, Lina Zhou, Xuemei Tang, Xi Yang, Hirokazu Kanegane, Xiaodong Zhao

Published in: European Journal of Pediatrics | Issue 2/2020

Abstract

X-linked lymphoproliferative syndrome (XLP) is a rare primary immunodeficiency disease that can be divided into two types: SAP deficiency (XLP1) and XIAP deficiency (XLP2), caused by mutations in the SH2D1A and XIAP genes, respectively. Few cases of XLP (particularly XIAP deficiency) have been reported in mainland China; hence, little is known about the characteristics of Chinese patients with XLP. We identified 13 and 7 patients with SAP and XIAP deficiency, respectively, in our center. Of our 20 patients, 19/20 (95%) presented with disease symptoms at a very early age: six in infancy and 13 in childhood. One XIAP- and three SAP-deficient patients died, while 3/7(42.9%) and 4/13(30.8%), respectively, developed hemophagocytic lymphohistiocytosis (HLH). Epstein-Barr virus (EBV) infection was significantly more common in SAP-deficient 10/13 (76.9%) than XIAP-deficient 2/7 (28.6%) patients, as was hypogammaglobulinemia (10/13 (76.9%) vs. 1/7 (14.3%)). None of the seven XIAP-deficient patients had colitis or lymphoma. Nine SAP-deficient patients and five XIAP-deficient patients showed markedly deficient SAP and XIAP expression, respectively, in lymphocytes. Significantly reduced levels of switched memory B cells were observed in six SAP-deficient patients with persistent hypogammaglobulinemia. One of 13 (7.7%) SAP-deficient patients and 1 of 7 (12.3%) XIAP-deficient patients have received HSCT treatment and are now alive and well; the other alive patients were waiting for HSCT. We also summarized clinical, genetic, and immunological characteristics of all 55 patients (including our 20 patients) reported in the literature in mainland China today.

Conclusion: The overall characteristics of SAP deficiency in mainland China were consistent with those in previous reports, whereas manifestations of XIAP deficiency varied significantly. None of inflammatory bowel disease (IBD) has been reported among XIAP-deficient patients in our center; however, whether Chinese XIAP-deficient patients will develop colitis in the future warrants further investigation. HSCT is the only curative therapy for XLP and this therapy should be urgently considered.

What is Known: • SAP and XIAP deficiencies share common clinical feature, HLH, whereas they also have their own specific manifestations. • IBD affects 25–30% of XIAP-deficient patients, which has been reported in other countries especially in European country and Japan.
What is New: • This is the largest patient cohort study of XLP in China. • We firstly summarized the clinical features and outcomes of Chinese XIAP-deficient patients and found only 1 in 22 patients developed IBD and diet background may contribute to it; Asian SAP-deficient patients carrying SH2D1A R55X mutation were more prone to HLH.

Available only for authorised users

Aguilar C, Lenoir C, Lambert N, Bègue B, Brousse N, Canioni D, Berrebi D, Roy M, Gérart S, Chapel H, Schwerd T, Siproudhis L, Schäppi M, Al-Ahmari A, Mori M, Yamaide A, Galicier L, Neven B, Routes J, Uhlig HH, Koletzko S, Patel S, Kanegane H, Picard C, Fischer A, Bensussan NC, Ruemmele F, Hugot J-P, Latour S (2014) Characterization of Crohn disease in X-linked inhibitor of apoptosis–deficient male patients and female symptomatic carriers. J Allergy Clin Immunol 134:1131–1141.e9. https://doi.org/10.1016/j.jaci.2014.04.031 CrossRefPubMed

An Y-F, Luo X-B, Yang X, Wang J, Li L, Zhao X-D (2014) Clinical and molecular characteristics of Chinese patients with X-linked lymphoproliferative syndrome type 1: XLP1 in China. Pediatr Blood Cancer 61:2043–2047. https://doi.org/10.1002/pbc.25126 CrossRefPubMed

Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, Haber DA, Nichols KE (2001) Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 97:1131–1133. https://doi.org/10.1182/blood.V97.4.1131 CrossRefPubMed

Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, Heath PT, Steward CG, Smith O, O’Meara A, Kerrigan H, Mahlaoui N, Cavazzana-Calvo M, Fischer A, Moshous D, Blanche S, Schmid JP, Latour S, de Saint-Basile G, Albert M, Notheis G, Rieber N, Strahm B, Ritterbusch H, Lankester A, Hartwig NG, Meyts I, Plebani A, Soresina A, Finocchi A, Pignata C, Cirillo E, Bonanomi S, Peters C, Kalwak K, Pasic S, Sedlacek P, Jazbec J, Kanegane H, Nichols KE, Hanson IC, Kapoor N, Haddad E, Cowan M, Choo S, Smart J, Arkwright PD, Gaspar HB (2010) X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 117:53–62. https://doi.org/10.1182/blood-2010-06-284935 CrossRefPubMed

Chen Y, Wang Z, Luo Z, Zhao N, Yang S, Tang Y (2016) Comparison of Th1/Th2 cytokine profiles between primary and secondary haemophagocytic lymphohistiocytosis. Ital J Pediatr 42. https://doi.org/10.1186/s13052-016-0262-7

Chen X, Wang F, Zhang Y, Teng W, Wang M, Nie D, Zhou X, Wang D, Zhao H, Zhu P, Liu H (2018) Genetic variant spectrum in 265 Chinese patients with hemophagocytic lymphohistiocytosis: molecular analyses of PRF1, UNC13D, STX11, STXBP2, SH2D1A, and XIAP. Clin Genet 94:200–212. https://doi.org/10.1111/cge.13363 CrossRefPubMed

Chiba M (2019) Westernized diet is the most ubiquitous environmental factor in inflammatory bowel disease. Perm J. https://doi.org/10.7812/TPP/18-107

Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, Cahn AP, Durham J, Heath P, Wray P, Pavitt R, Wilkinson J, Leversha M, Huckle E, Shaw-Smith CJ, Dunham A, Rhodes S, Schuster V, Porta G, Yin L, Serafini P, Sylla B, Zollo M, Franco B, Bolino A, Seri M, Lanyi A, Davis JR, Webster D, Harris A, Lenoir G, de St Basile G, Jones A, Behloradsky BH, Achatz H, Murken J, Fassler R, Sumegi J, Romeo G, Vaudin M, Ross MT, Meindl A, Bentley DR (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20:129–135. https://doi.org/10.1038/2424 CrossRefPubMed

Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R (2003) SAP is required for generating long-term humoral immunity. Nature 421:282–287. https://doi.org/10.1038/nature01318 CrossRefPubMed

10.

Damgaard RB, Fiil BK, Speckmann C, Yabal M, Zur Stadt U, Bekker-Jensen S, Jost PJ, Ehl S, Mailand N, Gyrd-Hansen M (2013) Disease-causing mutations in the XIAPBIR2 domain impair NOD2-dependent immune signalling: XLP2 mutations abrogate NOD2 signalling. EMBO Mol Med 5:1278–1295. https://doi.org/10.1002/emmm.201303090 CrossRefPubMedPubMedCentral

11.

Ding Y, Zhou L, Xia Y, Wang W, Wang Y, Li L, Qi Z, Zhong L, Sun J, Tang W, Liang F, Xiao H, Qin T, Luo Y, Zhao X, Shu Z, Ru Y, Dai R, Wang H, Wang Y, Zhang Y, Zhang S, Gao C, Du H, Zhang X, Chen Z, Wang X, Song H, Yang J, Zhao X (2018) Reference values for peripheral blood lymphocyte subsets of healthy children in China. J Allergy Clin Immunol 142:970–973.e8. https://doi.org/10.1016/j.jaci.2018.04.022 CrossRefPubMed

12.

Horn PC, Belohradsky BH, Urban C, Weber-Mzell D, Meindl A, Schuster V (2011) Two new families with X-linked inhibitor of apoptosis deficiency and a review of all 26 published cases. J Allergy Clin Immunol 127:544–546. https://doi.org/10.1016/j.jaci.2010.11.040 CrossRefPubMed

13.

Hu HL, Chen HY, Hu B, Liu G (2013) Clinical features and mutational analysis of four cases of X-Linked lymphoproliferative syndrome. Chin J Appl Clin Pediatr 28(21):1629–1632

14.

Hügle B, Suchowerskyj P, Hellebrand H, Adler B, Borte M, Sack U, Overberg-Schmidt US, Strnad N, Otto J, Meindl A, Schuster V (2004) Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease—report of three cases. J Clin Immunol 24:515–522. https://doi.org/10.1023/B:JOCI.0000040922.26286.36 CrossRefPubMed

15.

Jiang J, Tang W, An Y, Tang M, Wu J, Qin T, Zhao X (2016) Molecular and immunological characterization of DNA ligase IV deficiency. Clin Immunol 163:75–83. https://doi.org/10.1016/j.clim.2015.12.016 CrossRefPubMed

16.

Jiang M-Y, Guo X, Sun S-W, Li Q, Zhu Y-P (2016) Successful allogeneic hematopoietic stem cell transplantation in a boy with X-linked inhibitor of apoptosis deficiency presenting with hemophagocytic lymphohistiocytosis: a case report. Exp Ther Med 12:1341–1344. https://doi.org/10.3892/etm.2016.3498 CrossRefPubMedPubMedCentral

17.

Jin Y-Y, Zhou W, Tian Z-Q, Chen T-X (2016) Variable clinical phenotypes of X-linked lymphoproliferative syndrome in China: report of five cases with three novel mutations and review of the literature. Hum Immunol 77:658–666. https://doi.org/10.1016/j.humimm.2016.06.005 CrossRefPubMed

18.

Kanegane H (2019) Inflammatory bowel diseases and primary immunodeficiency diseases. Immunol Med:1–8. https://doi.org/10.1080/25785826.2018.1556025 CrossRef

19.

Kanegane H, Yang X, Zhao M, Yamato K, Inoue M, Hamamoto K, Kobayashi C, Hosono A, Ito Y, Nakazawa Y, Terui K, Kogawa K, Ishii E, Sumazaki R, Miyawaki T (2012) Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis: XLP-1 in Japan. Pediatr Allergy Immunol 23:488–493. https://doi.org/10.1111/j.1399-3038.2012.01282.x CrossRefPubMed

20.

Lankester AC, Visser LFA, Hartwig NG, Bredius RGM, Gaspar HB, van der Burg M, van Tol MJD, Gross TG, Egeler RM (2005) Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplant 36:99–105. https://doi.org/10.1038/sj.bmt.1705016 CrossRefPubMed

21.

Li W, Chen J, Zhao Q, Dai R, Wang Y, Zhao H, Chen X, Xue X, Sun X, Tang X, Yu Y, Ding Y, Zhao X, Zhang Z (2017) Two families of X-linked lymphoproliferative disease type 1 characterized by agammaglobulinemia. Chin J Pediatr 55(5):377–382. https://doi.org/10.3760/cma.j.issn.0578-1310.2017.05.014 CrossRef

22.

Lyu X, Guo Z, Li Y, Fan R, Song Y (2018) Identification of a novel nonsense mutation in SH2D1A in a patient with X-linked lymphoproliferative syndrome type 1: a case report. BMC Med Genet 19. https://doi.org/10.1186/s12881-018-0576-y

23.

Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH (2010) XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 116:1079–1082. https://doi.org/10.1182/blood-2010-01-256099 CrossRefPubMedPubMedCentral

24.

Marsh RA, Rao K, Satwani P, Lehmberg K, Muller I, Li D, Kim M-O, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper J, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan MB, Bleesing JJ, Filipovich AH (2013) Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood 121:877–883. https://doi.org/10.1182/blood-2012-06-432500 CrossRefPubMedPubMedCentral

25.

Meazza R, Tuberosa C, Cetica V, Falco M, Parolini S, Grieve S, Griffiths GM, Sieni E, Marcenaro S, Micalizzi C, Montin D, Fagioli F, Moretta A, Mingari MC, Moretta L, Notarangelo LD, Bottino C, Aricò M, Pende D (2014) Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol 134:1381–1387.e7. https://doi.org/10.1016/j.jaci.2014.04.043 CrossRefPubMed

26.

Morra M, Silander O, Calpe S, Choi M, Oettgen H, Myers L, Etzioni A, Buckley R, Terhorst C (2001) Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 98:1321–1325. https://doi.org/10.1182/blood.V98.5.1321 CrossRefPubMed

27.

Nishida N, Yang X, Takasaki I, Imai K, Kato K, Inoue Y, Imamura T, Miyashita R, Kato F, Yamaide A, Mori M, Saito S, Hara J, Adachi Y, Miyawaki T, Kanegane H (2015) Dysgammaglobulinemia Associated With Glu349del, a Hypomorphic XIAP Mutation. J Investig Allergol Clin Immunol 25(3):205–213PubMed

28.

Ono S, Okano T, Hoshino A, Yanagimachi M, Hamamoto K, Nakazawa Y, Imamura T, Onuma M, Niizuma H, Sasahara Y, Tsujimoto H, Wada T, Kunisaki R, Takagi M, Imai K, Morio T, Kanegane H (2017) Hematopoietic stem cell transplantation for XIAP deficiency in Japan. J Clin Immunol 37:85–91. https://doi.org/10.1007/s10875-016-0348-4 CrossRefPubMed

29.

Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, Ochs HD, Wolf H, Bonnefoy J-Y, Biassoni R, Moretta L, Notarangelo LD, Moretta A X-linked Lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus–infected cells. J Exp Med 192(3):337–346. https://doi.org/10.1084/jem.192.3.337 CrossRef

30.

Purtilo DT, Yang JPS, Cassel CK, Harper R, Stephenson SR, Landing BH, Vawter GF (1975) X-linked recessive progressive combined variable immunodeficiency (Duncan’S Disease). Lancet 305:935–941. https://doi.org/10.1016/S0140-6736(75)92004-8 CrossRef

31.

Rigaud S, Fondanèche M-C, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Saint Basile G, Latour S (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 444:110–114. https://doi.org/10.1038/nature05257 CrossRefPubMed

32.

Schimmer AD, Dalili S, Batey RA, Riedl SJ (2006) Targeting XIAP for the treatment of malignancy. Cell Death Differ 13:179–188. https://doi.org/10.1038/sj.cdd.4401826 CrossRefPubMed

33.

Schmid JP, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, Kanegane H, Lopez-Granados E, Mejstrikova E, Pellier I, Galicier L, Galambrun C, Barlogis V, Bordigoni P, Fourmaintraux A, Hamidou M, Dabadie A, Le Deist F, Haerynck F, Ouachee-Chardin M, Rohrlich P, Stephan J-L, Lenoir C, Rigaud S, Lambert N, Milili M, Schiff C, Chapel H, Picard C, de Saint Basile G, Blanche S, Fischer A, Latour S (2011) Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 117:1522–1529. https://doi.org/10.1182/blood-2010-07-298372 CrossRef

34.

Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, Okano M, Lanyi A, Sumegi J (1995) X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 38:471–478. https://doi.org/10.1203/00006450-199510000-00001 CrossRefPubMed

35.

Speckmann C, Lehmberg K, Albert MH, Damgaard RB, Fritsch M, Gyrd-Hansen M, Rensing-Ehl A, Vraetz T, Grimbacher B, Salzer U, Fuchs I, Ufheil H, Belohradsky BH, Hassan A, Cale CM, Elawad M, Strahm B, Schibli S, Lauten M, Kohl M, Meerpohl JJ, Rodeck B, Kolb R, Eberl W, Soerensen J, von Bernuth H, Lorenz M, Schwarz K, Zur Stadt U, Ehl S (2013) X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 149:133–141. https://doi.org/10.1016/j.clim.2013.07.004 CrossRefPubMed

36.

Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, Klein G, Seri M, Wakiguchi H, Purtilo DT, Gross TG (2000) Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 96(9):3118–3125PubMed

37.

Sun J, Ying W, Liu D, Hui X, Yu Y, Wang J, Wang X (2013) Clinical and genetic features of 5 chinese patients with X-linked lymphoproliferative Syndrome. Scand J Immunol 78:463–467. https://doi.org/10.1111/sji.12103 CrossRefPubMed

38.

Talaat KR, Rothman JA, Cohen JI, Santi M, Choi JK, Guzman M, Zimmerman R, Nallasamy S, Brucker A, Quezado M, Pittaluga S, Patronas NJ, Klion AD, Nichols KE (2009) Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. Pediatr Blood Cancer 53:1120–1123. https://doi.org/10.1002/pbc.22185 CrossRefPubMedPubMedCentral

39.

Wicki S, Gurzeler U, Wei-Lynn Wong W, Jost PJ, Bachmann D, Kaufmann T (2016) Loss of XIAP facilitates switch to TNFα-induced necroptosis in mouse neutrophils. Cell Death Dis 7:–e2422. https://doi.org/10.1038/cddis.2016.311 CrossRef

40.

Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, Serpe JM, Dasu T, Tschannen MR, Veith RL, Basehore MJ, Broeckel U, Tomita-Mitchell A, Arca MJ, Casper JT, Margolis DA, Bick DP, Hessner MJ, Routes JM, Verbsky JW, Jacob HJ, Dimmock DP (2011) Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 13:255–262. https://doi.org/10.1097/GIM.0b013e3182088158 CrossRefPubMed

41.

Xu L, Luo Y, Yu J, Lou J, Fang Y, Chen J (2018) X-linked inhibitor of apoptosis deficiency manifested as Crohn’s disease: a case report and literature review. Chin J Pediatr 56(1):43–47. https://doi.org/10.3760/cma.j.issn.0578-1310.2018.01.011 CrossRef

42.

Yang X, Kanegane H, Nishida N, Imamura T, Hamamoto K, Miyashita R, Imai K, Nonoyama S, Sanayama K, Yamaide A, Kato F, Nagai K, Ishii E, van Zelm MC, Latour S, Zhao X-D, Miyawaki T (2012) Clinical and genetic characteristics of XIAP deficiency in Japan. J Clin Immunol 32:411–420. https://doi.org/10.1007/s10875-011-9638-z CrossRefPubMed

43.

Zeissig Y, Petersen B-S, Milutinovic S, Bosse E, Mayr G, Peuker K, Hartwig J, Keller A, Kohl M, Laass MW, Billmann-Born S, Brandau H, Feller AC, Röcken C, Schrappe M, Rosenstiel P, Reed JC, Schreiber S, Franke A, Zeissig S (2015) XIAP variants in male Crohn’s disease. Gut 64:66–76. https://doi.org/10.1136/gutjnl-2013-306520 CrossRefPubMed

44.

Zhizhuo H, Junmei X, Yuelin S, Qiang Q, Chunyan L, Zhengde X, Kunling S (2012) Screening the PRF1, UNC13D, STX11, SH2D1A, XIAP, and ITK gene mutations in Chinese children with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 58:410–414. https://doi.org/10.1002/pbc.23216 CrossRefPubMed

45.

Zhou S, Ma H, Gao B, Fang G, Zeng Y, Zhang Q, Qi G (2017) Characterization of a novel disease-causing mutation in exon 1 of SH2D1A gene through amplicon sequencing: a case report on HLH. BMC Med Genet 18. https://doi.org/10.1186/s12881-017-0376-9

46.

Zhu DX, Du J, Lan HK, Yu L, Feng ZC (2007) Clinical and gene research of X-linked lymphoproliferative disease in a Chinese family. Zhonghua Yi Xue Za Zhi 87(4):244–248 23, ChinesePubMed

Title: X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic
Authors: Tao Xu
Qin Zhao
Wenyan Li
Xuemei Chen
Xiuhong Xue
Zhi Chen
Xiao Du
Xiaoming Bai
Qian Zhao
Lina Zhou
Xuemei Tang
Xi Yang
Hirokazu Kanegane
Xiaodong Zhao
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
Chronic Inflammatory Bowel Disease
Epstein-Barr Virus
Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis
Published in: European Journal of Pediatrics / Issue 2/2020
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-019-03512-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Follow-up study of patients admitted to the pediatric emergency department for chest pain

Correlation of lateral ventricular size and deep gray matter volume in MRI at term equivalent age with neurodevelopmental outcome at a corrected age of 24 months and with handedness in preterm infants

Interventions to reduce bruxism in children and adolescents: a systematic scoping review and critical reflection

Outcomes of hypoplastic left heart syndrome: analysis of National Inpatient Sample Database 1998–2004 versus 2005–2014

Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study

The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review